Dysregulation of the miR-25-IMPA2 axis promotes metastatic progression in clear cell renal cell carcinoma

Yuh-Feng Lin a,b,1, Jian-Liang Chou a, Jeng-Shou Chang c, I-Jen Chiu a,b, Hui-Wen Chiu a,b,1, Yuan-Feng Lin a,d,*

a Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
b Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
c Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
d Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

1 These authors equally contributed to this study.

⁎ Corresponding author at: Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
E-mail address: d001089012@tmu.edu.tw (Y.-F. Lin).

1 These authors equally contributed to this study.

ARTICLE INFO

Article history:
Received 11 November 2018
Received in revised form 1 June 2019
Accepted 5 June 2019
Available online 12 June 2019

Keywords:
Renal cell carcinoma
Metastasis
IMPA2
MicroRNA
Biomarker

Abstract

Background: The molecular mechanism underlying clear cell renal cell carcinoma (ccRCC) metastasis remains unclear. We therefore aimed to elucidate the role of IMPA2 in ccRCC metastatic progression.

Methods: Using the Cancer Genome Atlas (TCGA) database and immunohistochemistry (IHC) staining, we investigated differences in IMPA2 mRNA and protein expression, as well as their clinical relevance, in ccRCC. To investigate the function of IMPA2 in ccRCC metastasis, we performed in vitro migration and in vivo lung colony-forming assays. We further explored the effect of microRNA (miR)-25 on IMPA2 expression by performing a luciferase reporter assay.

Findings: We show that ccRCC expresses relatively lower transcript levels of IMPA2 than normal kidney tissue. IMPA2 downregulation was greater in high-grade ccRCC than in low-grade ccRCC and was correlated with a poor prognosis in ccRCC patients. Importantly, we demonstrate that IMPA2 expression is inversely associated with the metastatic potential of ccRCC cells. We found that IMPA2 knockdown promotes, but overexpression suppresses, the cellular migration and lung colony-forming abilities of ccRCC cells. By using in silico and luciferase reporter assays, we found that IMPA2 expression is primarily influenced by miR-25 in ccRCC cells. Significantly, the inhibition of miR-25 function restored IMPA2 expression, thereby diminishing the metastatic potential of ccRCC cells.

Interpretation: We conclude that miR-25-mediated IMPA2 downregulation constitutes a novel signature for cancer metastasis and poor outcomes in ccRCC. We further postulate that the therapeutic targeting of miR-25 can be useful for preventing the metastatic progression of ccRCC associated with IMPA2 downregulation.

Funding: This study was supported by the Ministry of Science and Technology, Taiwan (MOST 107-2314-B-038-094, MOST 106-2314-B-038-069-MY3, MOST 105-2320-B-038-021-MY3 and MOST 107-2320-B-038-056).

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Renal cell carcinoma (RCC) is the most common type of malignant adult kidney tumor. Approximately 75% of RCC patients have the clear cell renal cell carcinoma (ccRCC) subtype [1]. Approximately 30% of ccRCC cases develop metastases, and 20 to 40% of patients show recurrence after cancer resection [2]. Metastasizing tumor cells spread out from the original lesions via invading the lymphatics or entering the circulation [3]. Lung metastases are common and are the result of metastatic spread to the lungs from a variety of tumor types, including RCC [4].

Despite the clear importance of metastasis, the process is still incompletely characterized at the molecular and biochemical levels. There are numerous targeted therapy agents approved for clinical use in metastatic RCC. These agents target the vascular epithelial growth factor (VEGF) pathway or are mammalian target of rapamycin (mTOR) inhibitors [5]. Many RCC patients receiving targeted therapy develop acquired resistance and experience subsequent tumor progression. Therefore, there is an urgent need to identify a new therapeutic target to treat RCC [6].

Inositol monophosphatase (IMPase) is an enzyme that dephosphorylates myo-inositol monophosphate to generate free myo-inositol. This enzymatic pathway is critical in cellular functions because myo-inositol is the substrate for the synthesis of the membrane lipid phosphatidylinositol (PI). The dephosphorylation of myo-inositol monophosphate by IMPase is a rate-limiting step for the regeneration
Research in context

Evidence before this study

Clear cell renal cell carcinoma (ccRCC) is the most common type of RCC and named from the deposition of high lipid content in the cytoplasm. Approximately 30% of clear cell renal cell carcinoma (ccRCC) cases develop metastases, and 20 to 40% of patients show recurrence after surgery. Metastatic spread to lungs is extensively found in clinical ccRCC patients; however, molecular mechanism underlying ccRCC metastasis remains largely unknown. Therefore, it is urgently needed to unlock the molecular mechanism for ccRCC metastatic progression and identify a new therapeutic target for combating ccRCC metastasis.

Added value of this study

Here we find that IMPA2 downregulation is commonly detected in high-grade ccRCC and refers to a poor prognosis in ccRCC patients. In addition, IMPA2 knockdown or overexpression negatively modulates the metastatic ability of ccRCC cells. Furthermore, we identified that a dysregulation of miR-25-3p determines the IMPA2-modulated metastatic progression in ccRCC. In summary, this study demonstrated that the miR-25-IMPA2 axis plays a critical role in driving ccRCC metastasis.

Implications of all the available evidence

This study identified a novel miR-25-IMPA2 axis that modulates the metastatic potentials of ccRCC, and suggested that miR-25-IMPA2 axis servers as a clinical biomarker and a promising therapeutic target for ccRCC metastasis.

2. Material & methods

2.1. Clinical and molecular data for RCC patients

The clinical information for the patients in the TCGA RCC cohort, including age, gender, cancer grade, cancer stage, TNM stage, and overall survival (OS) time, was collected from the TCGA website (Supplementary Tables 1 and 2). The molecular data for the TCGA RCC cohort, which were obtained by RNAseq (polyA þ Illumina HiSeq) analysis, were also downloaded from the UCSC Xena website (http://xena.ucsc.edu/welcome-to-ucsc-xena/).

2.2. Immunohistochemistry (IHC) staining analysis

RCC tissue microarrays were purchased from SuperBioChips (Seoul, Korea) and the detailed information on all tumor specimens can be found at http://www.tissue-array.com/main.html and Supplementary Table 3. For IHC staining, paraffin-embedded tumor sections (3 μm thickness) were heated, deparaffinized using xylene, and rehydrated in a graded series of ethanol with a final wash in tap water. Antigen retrieval was performed with Target Retrieval Solution (DAKO) in a Decloaking Chamber (Biocare Medical). Endogenous peroxidase activity was quenched with hydrogen peroxide. The sections were then incubated with anti-IMPA2 antibody (Sigma-Aldrich Cat# HPA029561) at 4 °C overnight. A VECTASTAIN ABC peroxidase system (Vector Laboratories) was used to detect the reaction products. IHC intensity of the IMPA2 protein was recorded by combining a four-tier scale (0, negative; 1+, week; 2+, moderate; 3+, strong) without (for Kaplan-Meier analysis) or with (for paired normal and tumor tissues) staining percentage (0–100%) in tissues derived from ccRCC patients.

2.3. Cell culture

The human renal adenocarcinoma cell line 769-P was obtained from ATCC; the cells were maintained in RPMI 1640 medium supplemented with 10% FBS, penicillin (100 μg/ml) and streptomycin (100 μg/ml) (Gibco Life Technologies). The human renal adenocarcinoma cell lines ACHN and A498 were purchased from ATCC; the cells were maintained in minimal essential medium (MEM) supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml). The human renal adenocarcinoma cell lines Caki-1 and Caki-2 were purchased from ATCC; the cells were maintained in RPMI 1640 medium supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml). All cells were incubated in 5% CO₂ at 37 °C.

2.4. Migration and invasion assays

In vitro migration and invasion was assessed by using a Boyden chamber assay (NeuroProbe, Gaithersburg, MD, USA). Cells (1.5 × 10⁴) in serum-free culture medium were added to the upper chamber of the device on a membrane with an 8.0 μm hole and pre-coated without (for migration) or with (for invasion) matrigel (Sigma-
Aldrovandii, and the lower chamber was filled with 10% FBS culture medium. After a 3 h (for migration) or 16 h (for invasion) incubation, the membrane was soaked in methanol for 10 min and stained with Giemsa, which was diluted 10-fold by double-distilled water, for 1 h. Then, the membrane was attached to slides, and the upper cells of the membrane were carefully removed with a cotton swab. The lower cells were photographed. The lower cells were quantified by counting the cells in three random areas under a microscope at 400× magnification.

2.5. miRNA-25-3p inhibitor and miR-25-3p/miR-25-3p transfection

Cells were seeded in six-well plates and transfected with 10 nM, 30 nM, or 100 nM miR-25-3p inhibitor or co-transfected with 100 nM miR-25-3p inhibitor with non-silencing or IMPA2 shRNA (0.3 μg of each) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s instructions. The miR-25-3p inhibitor was purchased from Thermo Fisher (Pittsburgh, PA, USA). After 24 h of the transfection, the cells were used for migration, RNA, and protein assays.

Low sensor backbone (LSB) plasmid containing miR-25-3p or miR-25-3p was a gift from Ron Weiss (Addgene plasmid # 103375; http://n2t.net/addgene:103375; RRID: Addgene_103,375) and stably transfected into A498 cells according to the procedure reported previously [18]. The miR-25-3p-expressing cells were further transiently transfected with pLAS3w/Pbsd plasmid containing without or with IMPA2 gene.

2.6. Lentiviruses production and transduction

Lentiviral IMPA2 shRNA constructs were purchased from the RNAi Core in Academia Sinica (Taipei, Taiwan). The mature antisense sequences of the IMPA2 shRNAs were as follows: shRNA1 (CDS), 5′-GCTGTTGCAGAAGCTGGTCTG-3′; shRNA2 (3′ UTR), 5′-AGAGGAGTTG TCAGCTACA-3′; shRNA3 (3′ UTR), 5′-AGCTCTCTCCTCACAGGATT-3′. The gene encoding IMPA2 was amplified from human cDNA (Invitrogen) using the standard polymerase chain reaction (PCR) procedure with paired primers (forward_5′-TAAGCAGCTAGCATGAAGCCG TGCGTGACTGAG-3′ and reverse_5′-TAAGCAGCTAGCATGAAGCCG TGCGTGACTGAG-3′). The PCR products were cloned into EcoRI/BamHI restriction sites of pHelper (Promega) and packaged into lentiviral plasmids containing the full-length of IMPA2 3′-UTR as template in the standard PCR procedure with PfuUltra high-fidelity DNA polymerase (Agilent) and paired primers (forward_5′-CCCCCGGAGTACTCGAAGT-3′ and reverse_5′-CCCGTGACTGTTGAGTACTCGAAGT-3′). Determining luciferase activity, ACHN cells were seeded in 6-well plates and transfected with pmIRGLO or pmIRGLO containing the IMPA2 3′-UTR variants. After 24 h, the luciferase activity was measured using a Dual-Glo® Luciferase Assay System (Promega). Briefly, the cells were lysed in lysis buffer containing luciferase substrate for 10 min. The total lysate was centrifuged at 12,000 rpm for 1 min, the supernatant was divided into 3 wells in a white 96-well plate, and the Renilla luminescence was normalized to that of the Renilla control.

2.7. Western blotting assay

Protein was extracted from cells using lysis buffer. After centrifugation, the protein content of the supernatant was quantified at 280 nm. Aliquots of 100 μg of total protein and HR Pre-Stained Protein Marker (10–170 kDa) (BIOTOOLS, Taiwan) were loaded onto each lane of a SDS gel and transferred to PVDF membranes. The membranes were incubated with blocking buffer (5% nonfat milk in TBS containing 0.1% Tween-20) for 2 h at room temperature. After that, the samples were probed with primary antibodies against IMPA2/Slug (Cell Signaling) and GAPDH (AbFrontier) overnight at 4°C. After extensive washing, the membranes were incubated with a secondary peroxidase-labeled IgG for 1 h at room temperature. Immunoreactive bands were visualized by enhanced chemiluminescence.

2.8. Reverse transcription polymerase chain reaction and real-time polymerase chain reaction

Total RNA was isolated from the cells using TRIzol reagent. cDNA was synthesized from 2 μg of total RNA with a Transcriptor First Strand cDNA Synthesis Kit (Roche). Specific primers (IMPA2: forward_5′-GCTG TTGGGGGGCAAGTGTG-3′ and reverse_5′-CTTCAGGTCGCA GGGACACCCTTGTTCTGGC-3′; miR25: forward_5′-GGGGGGCTCCAAAGTGCTGTT-3′ and reverse_5′-GGGGGACACCCTTGTTCTGGC-3′; CDH2: forward_5′-CTTGAGACCCCCTCTGTTGAAA TCG-3′ and reverse_5′-GCAAAGGAGTGGAGGATGAC-3′) GAPDH: forward_5′-ATAGATTCCACCCATGGCAAACTC-3′ and reverse_5′-GGTGTGTTATCCAGT-3′ and 2× PCR reagent were used for the 25–35 cycles of PCR. Power SYBR™ Green PCR Master Mix (Thermo Fisher) was used for real-time PCR. The mRNA levels were normalized to those of GAPDH. Fold changes were calculated using the 2−ΔΔCt method.

2.9. Luciferase reporter assay

The DNA sequence corresponding to the 3′ untranslated region (3′UTR) of IMPA2 at different lengths was amplified from human cDNA (Invitrogen) using the standard polymerase chain reaction (PCR) procedure with paired primers (forward_5′-TGCGTTGGTGTGCTGTG-3′ and reverse_5′-CCGGTCAAGCACA GAGGGCCATTTTGTGAC-3′) for full length; reverse_5′-CCGGTCAAGCAGG CATTGATCTTTA-3′ (for deletion). The PCR products of IMPA2 3′ UTR were inserted into the pmIRGLO plasmid (Promega) using Nhel/XbaI restriction sites. The side-directed mutagenesis for the miR-25-3p DNA-binding site was performed by using pmIRGLO plasmid containing the full-length of IMPA2 3′-UTR as template in the standard PCR procedure with PfuUltra high-fidelity DNA polymerase (Agilent) and paired primers (forward_5′-CCCCGGAGTACTCGAAGT-3′ and reverse_5′-CCGGTCAAGCAGCATTTGAC-3′). For determining luciferase activity, ACHN cells were seeded in 6-well plates and transfected with pmIRGLO or pmIRGLO containing the IMPA2 3′ UTR variants. After 24 h, the luciferase activity was measured using a Dual-Glo® Luciferase Assay System (Promega). Briefly, the cells were lysed in lysis buffer containing luciferase substrate for 10 min. The total lysate was centrifuged at 12,000 rpm for 1 min, the supernatant was divided between 3 wells in a white 96-well plate, and the firefly luminescence was measured. One volume of Dual-Cloφ Stop & Glo® reagent was added to each well. After 10 min, Renilla luminescence was measured. The level of firefly luminescence was normalized to that of the Renilla luminescence.

2.10. Animal study

NOD/SCID male mice (6–8 weeks old) were obtained from BioLASCO in Taiwan and maintained in compliance with the institutional policy. All animal procedures were approved by the Institutional Animal Care and Use Committee at Taipei Medical University (IACUC Approval No.: LAC-2017-0364). For the in vivo lung metastatic colonization assay, cells were implanted into mice through tail vein injection at a concentration of 1 × 10^6 cells/0.1 ml of PBS. The mice were sacrificed 15 weeks after cell injection, and the lungs were dissected for histological analyses. The metastatic lung nodules were quantified after H&E staining using a microscope.

2.11. Statistical analysis

Overall survival (OS) was assessed by Kaplan-Meier analysis using a log-rank test. Cox Regression test was used to analyze hazard ratio of variables in the univariable and multivariable modes. The t-test and one-way ANOVA Tukey’s post-hoc test were used to analyze the statistical significance of parametric data from 2 and more independent
samples, respectively. Non-parametric Wilcoxon Signed-Ranks test, Friedman test, Mann-Whitney U test and Kruskal-Wallis test were used to analyze data from 2 related samples, 3 or more related samples, 2 independent samples and 3 or more independent samples, respectively. Pearson and Spearman correlation tests were used to analyze parametric and non-parametric data, respectively. All statistical calculations were performed in the statistical package SPSS version 22.0 for Windows (SPSS, Inc., Chicago, IL).

3. Results

3.1. IMPA downregulation correlates with tumorigenesis, cancer progression and poor prognosis in ccRCC

We first analyzed the transcriptional profiles of IMPA1 and IMPA2 in clinical tissues from TCGA ccRCC patients. The data showed that the mRNA levels of IMPA2, but not IMPA1, were significantly ($p < .05$) downregulated in primary tumors compared to normal renal tissues (Fig. 1a and b). Moreover, in comparison with IMPA1 expression, IMPA2 downregulation in the grade 4 tumors was more predominant than that of normal renal tissues and the grades 1–3 tumors from ccRCC patients (Fig. 1c). Accordingly, immunohistochemistry (IHC) experiments demonstrated that IMPA2 protein levels were dramatically reduced in tumors compared to paired normal renal tissues from 6 ccRCC patients (Fig. 1d and e). Moreover, Kaplan-Meier analysis revealed that low levels of IMPA2 mRNA predicted poor overall survival rates in TCGA ccRCC patients using the SurvExpress program (Fig. 2a and b). Similarly, Kaplan-Meier analysis using IMPA2 protein levels from the IHC experiment showed that IMPA2 downregulation was related to a poor prognosis in ccRCC patients for overall survival probability (Fig. 2c and d) even though the numbers of enrolled patients and clinicopathological results were limited. Importantly, a Cox regression test indicated that high levels of IMPA2 mRNA correlated with good outcomes in the univariate mode and served as an independent factor to predict favorable outcomes in multivariate analyses with other pathologic variables, including age, gender, pT, pN, pM, stage and grade (Fig. 2e and f), as well as other risk factors reported previously, including p53, ki67, CD44, CA9 and PCNA (Figs. S1a and S1b) [19], in ccRCC patients.

3.2. IMPA2 downregulation is associated with metastatic progression in ccRCC

We next examined the endogenous levels of IMPA2 mRNA and protein in a panel of ccRCC cell lines including 769P, A498, ACHN, Caki-1 and Caki-2. The data showed that the endogenous IMPA2 mRNA and protein levels were very elevated in A498 cells but were relatively lower in ACHN cells (Fig. 3a and b). Conversely, the cellular migration abilities were relatively poor in A498 cells but were much stronger in ACHN cells (Fig. 3c and d). The negative correlation between IMPA2 mRNA levels and cellular migration abilities was statistically significant ($p = .037$) in the tested ccRCC cell lines (Fig. 3e). In clinical specimens, IMPA2 mRNA levels appeared to be significantly ($p < .0001$) downregulated in metastatic ccRCC tissues (Fig. 3f).

![Fig. 1. IMPA2 downregulation significantly correlates with tumorigenesis and cancer progression in ccRCC. (a) Heatmap for the transcriptional profiles of the IMPA1 and IMPA2 genes in normal (N) tissues and primary tumors (T) of different grades from the TCGA ccRCC database. (b and c) Boxplot for the mRNA levels of IMPA1 and IMPA2 in normal tissues ($n = 72$) and primary tumors ($n = 534$) (b) or normal tissues (NT, $n = 72$) and tumors with grade G1 ($n = 14$), G2 ($n = 229$), G3 ($n = 207$) or G4 ($n = 76$) (c), as shown in a. In b and c, the band inside the box is the second quartile (the median). The upper and lower lines of box are the third and first quartiles, respectively. Box plots have lines extending vertically from the whiskers indicating minimum and maximum of all of the data. The individual points indicate outliers. The significant differences were analyzed by independent sample t-test and Tukey's post-hoc test, respectively. Different letters in the boxplot indicate the statistical significance at $p < .05$. (d) Immunohistochemistry (IHC) staining for the IMPA2 protein in paired normal and tumor tissues from ccRCC patients #16, #21 and #30. (e) IHC intensity of the IMPA2 protein in paired normal and tumor tissues derived from 6 ccRCC patients. Statistical significance was estimated with a non-parametric Wilcoxon signed rank test.](https://example.com/fig1.png)
Knockdown (KD) of IMPA2 expression using 3 independent shRNA clones markedly enhanced the cellular migration ability (Fig. 4a and b) and decreased endogenous IMPA2 mRNA levels (Fig. 4c) in A498 cells. Robustly, the reconstitution of IMPA2 expression in the IMPA2-silenced A498 cells suppressed the IMPA2 KD-enhanced cellular migration ability (Fig. 4d and e) and elevated the IMPA2 mRNA levels (Fig. 4f) in a concentration-dependent manner. Similarly, the forced expression of the exogenous IMPA2 gene predominantly suppressed the cellular migration ability (Fig. 4g and h) but dramatically elevated the endogenous mRNA levels of IMPA2 (Fig. 4i) in ACHN cells with high metastatic potential. Although the negative correlation between the endogenous IMPA2 levels and cellular invasiveness appeared to be not significant, IMPA2 knockdown in A498 cells (Figs. S2a and S2b) suppressed but IMPA2 knockdown in A498 cells (Figs. S2c and S2d) enhanced the cellular invasion ability dramatically. The lung colony-forming assay demonstrated that IMPA2 knockdown significantly (p = .00022) promoted the formation of tumor foci of A498 cells in the lungs of tumor-bearing mice (Fig. 4j and k). Since epithelial-mesenchymal transition (EMT) plays important role in cancer metastasis, we next examined the expression of E-type marker CDH1 (E-cadherin) and M-type markers CDH2 (N-cadherin) and Slug. Our data showed that IMPA2 knockdown promotes metastatic potentials of A498 cells by triggering EMT as judged by CDH1 downregulation but CDH2/Slug upregulation. Conversely, IMPA2 overexpression suppressed metastatic ability in ACHN cells by reversing EMT as shown by CDH1 upregulation but CDH2/Slug downregulation (Fig. 4l).

3.3. MicroRNA-25 posttranscriptionally inhibits IMPA2 expression in highly metastatic ccRCC cells

To identify the possible microRNA(s) that binds the 3’ untranslated region (3’ UTR) and thereby posttranscriptionally inhibits the translation of the IMPA2 gene, we performed an in silico analysis using the TargetScan, miRTarbase and microRNA.org databases (Fig. 5a) and then identified 2 miRNA candidates, miR-146 and miR-25-3p (Fig. 5b). We inserted a full-length (192 base pairs) IMPA2 3’ UTR into a luciferase reporter plasmid (Fig. 5b) and then performed a luciferase activity assay in ACHN cells. The data showed that the construct containing the IMPA2 3’ UTR significantly (p < .001) suppressed luciferase activity compared to the empty vector control (Fig. 5c). However, the deletion and mutant
variants of the IMPA2 3’ UTR (Fig. 5b) did not affect the luciferase activity in comparison with the vector control (Fig. 5c). Furthermore, we analyzed the endogenous levels of miR-25 in the tested ccRCC cell lines and found that ACHN cells express very high levels of miR-25, but A498 cells exhibit relatively lower miR-25 levels (Fig. 5d). The endogenous levels of miR-25 appeared to be negatively correlated with IMPA2 mRNA levels in the examined ccRCC cell lines (Fig. 5e). The transfection of anti-miR-25-3p oligonucleotides into ACHN cells markedly rescued the endogenous IMPA2 mRNA and protein levels (Fig. 5f) but suppressed the cellular migration ability (Fig. 5g and h). To demonstrate that miR-25-3p promotes ccRCC progression through IMPA2, we further performed IMPA2 knockdown in ACHN cells that were co-transfected with anti-miR-25-3p oligonucleotides. The data showed that IMPA2 knockdown compared to non-silencing control dramatically reduces the RNA and protein levels of IMPA2 (Fig. 5i) and rescues the cellular migration ability in the anti-miR-25-3p oligonucleotide-treated ACHN cells (Fig. 5g and h). To demonstrate that miR-25-3p promotes ccRCC progression through IMPA2, we further performed IMPA2 knockdown in ACHN cells that were co-transfected with anti-miR-25-3p oligonucleotides. The data showed that IMPA2 knockdown compared to non-silencing control dramatically reduces the RNA and protein levels of IMPA2 (Fig. 5i) and rescues the cellular migration ability in the anti-miR-25-3p oligonucleotide-treated ACHN cells (Fig. 5g and h). In comparison with vector control, the restoration of exogenous IMPA2 gene markedly elevated the RNA and protein levels of IMPA2 (Fig. 5k) but suppressed the cellular migration ability in miR-25-3p-overexpressing A498 cells (Fig. 5l and Fig. S3b). These findings indicate a critical role of miR-25-3p/IMPA2 axis in driving ccRCC progression.

3.4. The combined signature of high miR-25 levels and low IMPA2 levels predicts a worse outcome in ccRCC patients

We next analyzed the transcriptional profiles of miR-25 and IMPA2 in primary tumors from TCGA ccRCC patients. We found that the expression of miR-25 was negatively correlated with IMPA2 transcript levels in the analyzed ccRCC tissues (Fig. 6a). Moreover, Kaplan-Meier analysis demonstrated that high miR-25 levels and the combination of high miR-25 levels and low IMPA2 levels are associated with a poorer prognosis in TCGA ccRCC patients (Fig. 6b and c). In addition, the combined signature of high miR-25 levels and low IMPA2 levels was not associated with age, was relatively associated with pathologic N and M status, and was significantly correlated with gender, pathologic T status, stage and grade in TCGA ccRCC patients (Fig. 6d). Importantly, the Cox regression test revealed that the combined signature of high miR-25 levels and low IMPA2 levels predicted an increased hazard ratio in univariate mode and served as an independent risk factor in multivariate mode under the condition of overall survival probability in TCGA ccRCC patients (Table 1).
Fig. 4. IMPA2 downregulation promotes metastatic progression in ccRCC cells. (a–c) Giemsa staining (a) and cell number (b) for the migrated cells in 3-hour transwell assays and quantitative PCR for IMPA2 gene expression (c) in A498 cells transfected without (parental, PT) or with a nonsilencing (NS) sequence or one of 3 independent IMPA2 shRNA clones. (d–f) Giemsa staining (d) and cell number (e) for the migrated cells in 3-hour transwell assays and quantitative PCR for IMPA2 gene expression (f) in IMPA2 shRNA clone #1 (targeting 3’ UTR)-overexpressing A498 cells transiently transfected with exogenous IMPA2 DNA in the designated amounts for 24 h. (g–i) Giemsa staining (g) and cell number (h) for the migrated cells in 3-hour transwell assays and quantitative PCR for IMPA2 gene expression (i) in ACHN cells stably transfected without (parental, PT) or with a vector control (VC) or a vector containing the IMPA2 gene. In b, c, e, f, h, and i, error bars represent the mean ± SEM of data obtained from three independent experiments. The different letters in each column of b, c, e, f, h, and i indicate the statistical significance at p < .05 as determined by Friedman test. (j) Hematoxylin/eosin staining for lung tissues derived from mice transplanted with A498 cells transfected with nonsilencing (NS) sequences or IMPA2 shRNA via tail-vein injections. The symbols (*) and red circles indicate the colonies of A498 cells. (k) Boxplot for the lung colonies counted from tumor-bearing mice (n = 5) as shown in j. The band inside the box is the second quartile (the median). The upper and lower lines of box are the third and first quartiles, respectively. Box plots have lines extending vertically from the whiskers indicating minimum and maximum of all of the data. The individual points indicate outliers. Mann-Whitney U test was used to estimate the statistical significance. (l) RT-PCR for CDH1, CDH2 and GAPDH genes and Western blotting (WB) for Slug and GAPDH proteins derived from A498 cells without (NS) or with IMPA2 knockdown (shIMPA2) and ACHN cells without (VC) or with IMPA2 overexpression (IMPA2). GAPDH was used as internal controls for RT-PCR and Western blot analyses.
Fig. 5. IMPA2 downregulation is mediated by the miR-25 posttranscriptional inhibition in ccRCC cells. (a) An in silico analysis of IMPA2-targeting microRNAs using the TargetScan, miRTarbase and microRNA.org databases. The numbers indicate the microRNAs that are computationally predicted to bind the 3′ untranslated region (3′ UTR) of the IMPA2 transcript. (b) Experimental designs for the cloning of the IMPA2 3′ UTR with no alteration (FL, full-length), with a deletion (Del) among base pairs (bp) 161–192 (numbered from the bp next to the stop codon) or with a mutation (mut) at the miR-25 binding sequences into the luciferase-expressing pmirGLO plasmid. (c) Luciferase activity in ACHN cells transiently transfected with the empty pmirGLO plasmid or the plasmid containing the IMPA2 3′ UTR without alterations (FL) or with a deletion (Del 161–192) or miR-25 binding site mutation. One-way ANOVA with Tukey’s test was used to estimate the statistical significance. (d) RT-PCR (upper) and quantitative PCR (bottom) analyses for miR-25 and GAPDH expression in a panel of ccRCC cell lines. GAPDH was used as an internal control and was utilized to normalize the miR-25 levels in quantitative PCR. (e) Scatchard plot for the endogenous IMPA2 mRNA levels from Fig. 3b and the miR-25 levels from d. Spearman’s correlation test was used to determine the statistical significance. (f) RT-PCR (upper), Western blot (middle) and quantitative PCR (Q-PCR, bottom) analyses for IMPA2 and GAPDH expression in ACHN cells transiently transfected with anti-miR-25-3p oligonucleotides at the designated concentrations for 24 h. GAPDH was used as an internal control. (g) Giemsa staining (g) and cell number (h) for the migrated cells in 3-h transwell assays for ACHN cells transiently transfected with anti-miR-25 oligonucleotides at the designated concentrations for 24 h. (i) RT-PCR (upper) and Western blot (bottom) analyses for IMPA2 and GAPDH expression in ACHN cells transiently transfected without or with anti-miR-25-3p oligonucleotides combining with non-silencing or IMPA2 shRNA for 24 h. GAPDH was used as an internal control. (j) Migrated cell number of ACHN cells without or with the designed transfections as shown in i. (k) RT-PCR (upper) and Western blot (bottom) analyses for IMPA2 and GAPDH expression in A498 cells without or with the overexpression of miR-25-5p or miR-25-3p combining without (vector control) or with the restoration of exogenous IMPA2 gene. GAPDH was used as an internal control. (l) Migrated cell number of A498 cells without or with the designed transfections as shown in k. In c, f, h, j and l, error bars represent the mean ± SEM of data obtained from three independent experiments. The different letters in each column of c, f, h, j and l indicate the statistical significance at p < .05 as determined by Friedman test.
4. Discussion

IMPA2 is a gene that encodes a catalytic protein that converts inositol monophosphate into free inositol through dephosphorylation [20]. Inositol regulates N712 genes and is involved in many intracellular signaling pathways [21]. Previous studies have suggested that a promoter polymorphism of IMPA2 contributes to the risk of schizophrenia by elevating transcription activity in Han Chinese individuals [22]. Another recent study concluded that a potential association exists between single nucleotide polymorphisms in the IMPA2 gene and increased risk of ischemic stroke [23]. Lithium, which inhibits IMPase, is a major therapeutic agent for bipolar disorder and inhibits two important biochemical systems: the inositol signaling pathway and GSK-3β function [24]. However, there are few published articles describing the relationship between IMPA2 and cancer. French et al. indicated that the expression of the IMPA2 gene accounts for more variation in methotrexate polyglutamates in leukemia cells than in normal cell lines [12]. Our data showed that the expression of IMPA2 is predominantly downregulated in primary tumors compared to normal tissues derived from patients with ccRCC (Fig. 1b, d and e). Moreover, IMPA2 expression levels were significantly correlated with disease grade (Fig. 1a and c). Patients with low IMPA2 expression had significantly worse OS than those with high IMPA2 expression (Figs. 2a-d). In addition, comparing IMPA2 expression with clinicopathological factors in affecting the survival of ccRCC patients, lower IMPA2 expression was significantly correlated with poor OS in univariate and multivariate analysis (Fig. 2ea n df).

**Fig. 6.** The combined signature of high miR-25 transcript levels and low IMPA2 transcript levels predicts a worse prognosis in ccRCC patients. (a) Scatchard plot for IMPA2 and miR-25 mRNA levels from the TCGA ccRCC database. Pearson’s correlation test was used to determine the statistical significance of IMPA2 and miR-25 expression in primary tumors derived from patients diagnosed with G1-G2 (blue dots), G3-G4 (orange dots) or G1-G4 (blue and orange dots) ccRCC. (b and c) Kaplan-Meier analyses for miR-25 mRNA levels (b) or miR-25 and IMPA2 mRNA levels (c) in TCGA ccRCC patients (n = 237). The high and low expression levels of miR-25 and IMPA2 were determined by the median of their mRNA levels in primary tumors from the TCGA ccRCC database. (d) Chi-square test for the combined signature of miR-25 and IMPA2 mRNA levels and pathologic variables including age, gender, pT, pN, pM, stage and grade from the TCGA ccRCC database. In c and d, the high (H) and low (L) expression levels of miR-25 and IMPA2 are presented as the signatures miR-25_L/IMPA2_H, others (miR-25_L/IMPA2_L and miR-25_H/IMPA2_H) and miR-25_H/IMPA2_L.

**Table 1**

| Variables | Univariable (HR, 95%CI) | P | Multivariable (HR, 95%CI) | P |
|-----------|-------------------------|---|---------------------------|---|
| **Age**   |                         |   |                           |   |
| <67       | 1                       | NA| 1.43 (0.92–2.19)          | 0.111 |
| ≥67       | 1.47 (0.97–2.23)        | 0.069| 1                          | NA |
| **Gender**|                         |   |                           |   |
| Female    | 1                       | NA| 1.74 (1.06–2.86)          | 0.029 |
| Male      | 1.05 (0.69–1.60)        | 0.827| 1                          | NA |
| **pT**    |                         |   |                           |   |
| T1-T2     | 1                       | NA| 1.08 (0.46–2.55)          | 0.853 |
| T3-T4     | 2.74 (1.79–4.17)        | <0.001| 1                          | NA |
| **pN**    |                         |   |                           |   |
| N0        | 1                       | NA| 1.33 (0.65–2.71)          | 0.437 |
| N1        | 2.95 (1.52–5.71)        | <0.001| 1                          | NA |
| **pM**    |                         |   |                           |   |
| M0        | 1                       | NA| 2.55 (1.50–4.32)          | <0.001 |
| M1        | 3.81 (2.46–5.92)        | <0.001| 1.50 (3.95)               | 0.377 |
| **Stage** |                         |   |                           |   |
| I-II      | 1                       | NA| 1.53 (0.59–3.95)          | 0.377 |
| II-III    | 3.10 (1.99–4.81)        | <0.001| 1                          | NA |
| III-IV    | 2.47 (1.56–3.92)        | <0.001| 1.74 (1.06–2.86)          | 0.029 |
| **miR-25/IMPA2 levels** |                 |   |                           |   |
| Low/high  | 3.22 (1.75–5.95)        | <0.001| 2.43 (1.21–4.91)          | 0.013 |

HR and CI denote hazard ratio and confidence interval, respectively.
increases free inositol and IP$_3$ [9]. Recent evidence has shown that IP$_3$ receptors (IP$_{3R}$s) are calcium (Ca$^{2+}$) channels and play important roles in tumor growth, aggressiveness and drug resistance via the modulation of different signaling pathways [27,28]. Shibao et al. indicated that knockdown of IP$_{3R}$3 in colorectal carcinoma cells increased apoptosis, while overexpression of IP$_{3R}$3 decreased apoptosis [29]. Another recent study concluded that high levels of IP$_{3R}$3 were associated with increased metastasis in the lymph nodes and liver and with decreased 5-year survival [30]. Therefore, IP$_{3R}$s may be regulated by proto-oncogenes and tumor-suppressor proteins [28,31]. In our in vitro study, endogenous IMPA2 levels were inversely correlated with metastatic capability in a panel of ccRCC cell lines (Fig. 3). Silencing IMPA2 expression appeared to effectively increase the metastatic colonization of A498 cells in vitro and in the lungs of tumor-bearing mice (Fig. 4). Furthermore, IMPA2 overexpression inhibited the metastatic ability of ACHN cells (Fig. 4). These findings demonstrate that IMPA2 is likely correlated with the metastatic progression of ccRCC.

Our results revealed that miR-25 levels are negatively associated with IMPA2 expression in ccRCC tissues and that miR-25 probably inhibits IMPA2 expression by targeting the 3′ untranslated region of IMPA2 transcripts in ccRCC cells (Figs. 5a-e and 6a). Moreover, inhibiting miR-25 suppressed the metastatic ability of ccRCC cells (Figs. 5f-h). To the best of our knowledge, this study is the first to describe the relationship between miR-25 and IMPA2. MiR-25, which is a member of the miR-106b-25 cluster, has been reported to be involved in the progression and development of many types of cancers [32]. Recent evidence has shown the upregulation of miR-25 in gastric cancer patients and patients with positive lymph node metastasis [33]. Conversely, miR-25 inhibits the proliferation, migration, and invasion of osteosarcoma by targeting SRY-related high-mobility group box 4 (SOX4). We found that patients with high miR-25 expression had significantly poorer OS than those with low miR-25 expression (Fig. 6b). Furthermore, both low miR-25 expression and high IMPA2 expression were low prognostic markers in ccRCC (Fig. 6c and d).

We have shown that downregulation of IMPA2 expression maintains the metastatic potential of human ccRCC tumor cells in vitro and in vivo. Furthermore, IMPA2 likely serves as a good prognostic marker. In addition, the dysregulation of miR-25 may result in IMPA2 downregulation and thereby promote metastatic progression in ccRCC. However, the complete mechanism by which IMPA2 disrupts cellular signaling in metastatic RCC is unknown and requires further investigation.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.06.006.

Acknowledgements
The authors would like to thank Dr. Michael Hsiao at the Genomics Research Center, Academia Sinica, Taiwan for kindly providing the ccRCC cell lines.

Funding sources
This study was supported by the Ministry of Science and Technology, Taiwan (MOST 107-2314-B-038-094, MOST 106-2314-B-038-069-MY3, MOST 105-2320-B-038-021-MY3 and MOST 107-2320-B-038-056).

Declaration of competing interests
The authors have declared no potential conflicts of interest.

Author contributions
Y-F Lin, J-L Chou, H-W Chiu and Y-F Lin performed and analyzed most of the experiments. J-S Chang and I-J Chiu provided intellectual and technical support for the in vitro and in vivo experiments. Y-F Lin, H-W Chiu and Y-F Lin oversaw and designed the study and experiments, analyzed the data, and cowrote the manuscript.

References
[1] Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62(2):118–28.
[2] Leibovich BC, Lohse CM, Crispin PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183(4):1309–15.
[3] Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3(1):55–63.
[4] Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, et al. Targeting metastatic cancer with nanotechnology. Nat Rev Cancer 2011;11(2):39–50.
[5] Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376(4):254–66.
[6] Small J, Washburn J, Millington K, Zhu J, Holder SL. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. Oncotarget 2017;8(36):5916–34.
[7] Parys JB, Decuypere JP, Bultynck G. Role of the inositol 1,4,5-trisphosphate receptor/IP3R (3) in cancer. Mol Cancer 2005;10:117–26.
[8] Fisher SK, Novak JE, Agranoff BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 2002;84(2):736–54.
[9] Tong Z, Meng X, Wang J, Wang L, MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma. Exp Ther Med 2017;14(5):5200–6.
[10] Yang F, Ma J, Tang Q, Zhang W, Fu Q, Sun J, et al. MicroRNA-543 promotes the proliferation and invasion of clear cell renal cell carcinoma cells by targeting Kruppel-like factor 6. Biomed Pharmacother 2017;97:616–23.
[11] He YH, Chen C, Shi Z. The biological roles and clinical implications of MicroRNAs in breast cancer. J Cell Mol Med 2010;14(9):2133–42.
[12] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[13] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
[14] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[15] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
[16] Yang F, Ma J, Tang Q, Zhang W, Fu Q, Sun J, et al. MicroRNA-543 promotes the proliferation and invasion of clear cell renal cell carcinoma cells by targeting Kruppel-like factor 6. Biomed Pharmacother 2017;97:616–23.
[17] He YH, Chen C, Shi Z. The biological roles and clinical implications of MicroRNAs in breast cancer. J Cell Mol Med 2010;14(9):2133–42.
[18] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[19] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
[20] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[21] Jesch SA, Zhao X, Wells MT, Henry SA. Genome-wide analysis reveals inositol, not glycogen, to be a new human metabolic gene during development and aging of human dorsal lateral prefrontal cortex. PLoS One 2015;10(7):e0132675.
[22] simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62(2):118–28.
[23] Zeng Y, Meng X, Wang J, Wang L, MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma. Exp Ther Med 2017;14(5):5200–6.
[24] Zeng Y, Ma J, Tang Q, Zhang W, Fu Q, Sun J, et al. MicroRNA-543 promotes the proliferation and invasion of clear cell renal cell carcinoma cells by targeting Kruppel-like factor 6. Biomed Pharmacother 2017;97:616–23.
[25] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
[26] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[27] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
[28] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[29] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
[30] French D, Wang Y, Cheng C, Raimondi SC, Mullighan CG, Downing JR, et al. Altered calcium signaling in cancer cells: proto-oncogenes and tumor-suppressor proteins. Dev Biol 2007;302(1):1–12.
[31] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1980;53:411–9.
Kang SS, Han KS, Ku BM, Lee YK, Hong J, Shin HY, et al. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res 2010;70(3):1173–83.

Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD, et al. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J Cell Biol 2004;166(2):193–203.

Caiazza C, Mallardo M. The roles of miR-25 and its targeted genes in development of human cancer. Microrna 2016;5(2):113–9.

P LA, Ahadi A, Zare A, Tarighi S, Zaheri M, Souri M, et al. Up-regulation of miR-21, miR-25, miR-93, and miR-106b in gastric cancer. Iran Biomed J 2018;22(6):367–73.